Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)

Market Cap	321.54B -11.4%
Revenue (ttm)	32.56B +11.6%
Net Income	8.12B +18.7%
EPS	1.22 +11.8%
Shares Out	6.62B
PE Ratio	39.87
Forward PE	34.82
Dividend	0.20 (0.41%)
Ex-Dividend Date	May 27, 2026

Volume	172,756,167
Open	49.01
Previous Close	48.67
Day's Range	48.43 - 53.31
52-Week Range	45.26 - 74.04
Beta	0.13
Analysts	Strong Buy
Price Target	81.14 (+53.3%)
Earnings Date	Aug 20, 2026

About SHA:600276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2025, SHA:600276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Analyst Summary

According to 20 analysts, the average rating for 600276 stock is "Strong Buy." The 12-month stock price target is ¥81.14, which is an increase of 53.30% from the latest price.

Price Target

¥81.14

(53.30% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 29, 2026

Data Sources Report a data error